Hepatocellular carcinoma (HCC) accounts for 75–85% of primary liver cancers and is prevalent in the Asia-Pacific region. Till now, trans-arterial chemoembolization (TACE) is still one of common modalities in managing unresectable intermediate-stage HCC. | Comparing stereotactic ablative radiotherapy SABR versus re-trans-catheter arterial chemoembolization re-TACE for hepatocellular carcinoma patients who had incomplete response after initial TACE TASABR A randomized controlled trial
